Upadacitinib

Upadacitinib is a selective and potent Janus kinase (JAK) 1 inhibitor approved for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis. It works by blocking JAK1-dependent cytokine signaling, reducing inflammation and immune response.

As a targeted therapy, Upadacitinib offers improved efficacy and safety profiles compared to traditional immunosuppressants. Our pharmaceutical-grade Upadacitinib API is manufactured under strict GMP conditions to ensure high purity and quality, suitable for clinical and commercial drug production.

Applications:

• Treatment of rheumatoid arthritis (RA)

• Used in ulcerative colitis, psoriatic arthritis, and eczema

• Development of JAK1 inhibitor-based pharmaceuticals

Specifications:

• Purity: ≥99% (HPLC)

• Appearance: White or off-white crystalline powder

• Packaging: Double-layer PE bag with aluminum foil drum

• Compliance: GMP / DMF available on request

Storage:
Store in a dry, cool, and ventilated environment. Avoid exposure to moisture and heat.